NVCT.US Nuvectis Pharma Inc

Healthcare Biotechnology USA Stocks
20.24 USD
Close of Nov 15, 2026
5.77 29.28
Market cap
USD 696M
P/E
-
P/B
5.50x
ROE
-45.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NVCT.US undervalued?

Graham number

The Graham number of Nuvectis Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nuvectis Pharma Inc fundamental analysis

No fundamental analysis for Nuvectis Pharma Inc yet.

Nuvectis Pharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nuvectis Pharma Inc

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. i…

Full company profile